Pliant shares plummet as Phase 2b lung fibrosis study paused
Pliant Therapeutics has slammed the brakes on enrollment and dosing in a mid-stage study of its lung disease candidate in a scenario that some analysts say they have “never seen before.” The West Coast biotech ...
Pliant Therapeutics has slammed the brakes on enrollment and dosing in a mid-stage study of its lung disease candidate in a scenario that some analysts say they have “never seen before.”
The West Coast biotech ...
